Insights on the Breast Cancer Liquid Biopsy Global Market to 2027 - Opportunity Analysis and Industry Forecasts

News provided by

May 21, 2021, 17:30 ET

DUBLIN, May 21, 2021 /PRNewswire/ -- The "Breast Cancer Liquid Biopsy Market by Product & Service, Circulating Biomarker and Application: Global Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

The global breast cancer liquid biopsy market was valued at $87,641 thousand in 2019, and is projected to reach $357,051 thousand by 2027, registering a CAGR of 19.2% from 2019 to 2027.

Breast cancer liquid biopsy is a non-invasive blood test that detects tumor DNA fragments and circulating tumor cells (CTCs), which are released into the blood from primary tumors and metastatic sites. Breast cancer liquid biopsy is a simple & precise alternative to surgical biopsy procedures, which allows physicians and surgeons to detect & treat breast cancer at an early stage and obtain tumor information through blood samples. Breast cancer liquid biopsy is particularly significant as it helps physicians to understand molecular changes and dynamics of breast cancer. Moreover, breast cancer recurrence is expected to be understood through well-timed breast cancer liquid biopsy techniques.

Rise in prevalence of breast cancer, increase in preference for noninvasive procedures, technological advancements in breast cancer liquid biopsy instruments, advantages of over solid tumor biopsy, and increase in patient awareness toward minimally invasive breast cancer liquid biopsy procedures are the key factors that fuel growth of the breast cancer liquid biopsy market. In addition, rise in funding for breast liquid biopsy R&D, favorable initiatives are undertaken by governments and global health organizations, and an increase in breast cancer liquid biopsy reagents approvals are another factor that contributes toward the growth of the market. However, limitations associated with liquid biopsy testing and lack of access and awareness regarding breast cancer liquid biopsy in underdeveloped countries are expected to hinder the growth of the market.

The global breast cancer liquid biopsy market is segmented on the basis of product & service, circulating biomarker, application, and region. By product & service, the market is categorized into reagent kits, instruments, and services. By circulating biomarker, it is segregated into circulating tumor cells, extracellular vesicles, and circulating tumor DNA. Depending on application, it is classified into diagnostics, prognostics, and risk assessment. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA

Key Benefits

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of four regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Key Topics Covered:

Chapter 1: Introduction

Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.2. Cxo Perspective

Chapter 3: Market Landscape
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Force Analysis
3.4. Top Player Positioning, 2019
3.4.1. Breast Cancer
3.4.2. All Cancer Types
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Increase in Demand for Safe and Non-Invasive Procedures
3.5.1.2. Surge in Global Prevalence Rate of Breast Cancer
3.5.1.3. Advantages of Breast Cancer Liquid Biopsy Tests Over Traditional Tests
3.5.2. Restraint
3.5.2.1. Lack of Access and Awareness in Underdeveloped Countries
3.5.3. Opportunity
3.5.3.1. High Growth Potential in Emerging Markets
3.5.4. Impact Analysis
3.6. Pricing Analysis
3.7. Reimbursement Scenario
3.8. Clinical Validations
3.9. Regulatory Landscape
3.10. List of Approved Liquid Biopsy Tests

Chapter 4: Breast Cancer Liquid Biopsy Market, by Product & Service
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Reagent Kits
4.2.1. Key Market Trends, Growth Factors, and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Analysis, by Country
4.3. Instruments
4.3.1. Key Market Trends, Growth Factors, and Opportunities
4.3.2. Market Size and Forecast
4.3.3. Market Analysis, by Country
4.4. Services
4.4.1. Key Market Trends, Growth Factors, and Opportunities
4.4.2. Market Size and Forecast
4.4.3. Market Analysis, by Country

Chapter 5: Breast Cancer Liquid Biopsy Market, by Circulating Biomarker
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Circulating Tumor Cells
5.2.1. Market Size and Forecast, by Region
5.2.2. Market Analysis, by Country
5.3. Extracellular Vesicles
5.3.1. Market Size and Forecast, by Region
5.3.2. Market Analysis, by Country
5.4. Circulating Tumor Dna
5.4.1. Market Size and Forecast, by Region
5.4.2. Market Analysis, by Country

Chapter 6: Breast Cancer Liquid Biopsy Market, by Application
6.1. Overview
6.1.1. Market Size and Forecast
6.2. Diagnostics
6.2.1. Market Size and Forecast, by Region
6.2.2. Market Analysis, by Country
6.3. Prognostics
6.3.1. Market Size and Forecast, by Region
6.3.2. Market Analysis, by Country
6.4. Risk Assessment
6.4.1. Market Size and Forecast, by Region
6.4.2. Market Analysis, by Country

Chapter 7: Breast Cancer Liquid Biopsy Market, by Region
7.1. Overview
7.2. North America
7.3. Europe
7.4. Asia-Pacific
7.5. LAMEA

Chapter 8: Company Profiles
8.1. Biocept Inc.
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.1.6. Key Strategic Moves and Developments
8.2. F. Hoffmann-La Roche Ltd. (Foundation Medicine, Inc.)
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.2.6. Key Strategic Moves and Developments
8.3. Fluxion Biosciences, Inc.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.4. Menarini Group (Menarini Silicon Biosystems, Inc.)
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Key Strategic Moves and Developments
8.5. Myriad Genetics, Inc.
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.6. Neogenomics Laboratories, Inc.
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves and Developments
8.7. Qiagen N. V.
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.7.6. Key Strategic Moves and Developments
8.8. Sysmex Corporation
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.9. Thermo Fisher Scientific, Inc.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.10. Guardant Health, Inc.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves and Developments

For more information about this report visit https://www.researchandmarkets.com/r/coetla

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets